Factor 8 Ehl denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for factor 8 ehl are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Your Extended Half-Life Factor VIII — Quantity Limits

UnitedHealthcare applies quantity limits (QL) to EHL Factor VIII products, capping the units or vials it will cover per dispensing period based on standard dosing assumptions for an average patient. If your prescriber ordered a quantity that exceeds UHC's default limit — for example, to achieve adequate prophylactic factor coverage given your body weight, bleeding phenotype, or pharmacokinetic (PK) profile — the excess will be automatically denied. This is one of the most common and most successfully appealed denials for Factor VIII therapy.

## Why This Denial Is Appealable

Hemophilia A treatment is highly individualized. The FDA-approved prescribing information for EHL Factor VIII products explicitly contemplates dose individualization based on the patient's weight, the severity of the bleed or prophylaxis target, and PK testing. UHC's quantity limit is a population-level default that cannot account for every patient's clinical reality. A well-documented medical-necessity appeal — showing why this patient requires the prescribed quantity — has a strong track record of success, particularly when supported by PK data.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial. For an ongoing prophylaxis regimen that cannot be safely reduced, request expedited review (72-hour decision).
• External review (ACA §2719): If internal appeal fails, you have approximately four months from the final denial to request independent external review. External reviewers in hemophilia cases frequently apply the FDA label's individualization language rather than the insurer's population-level limit.
• ERISA §503: Employer plan members may demand the full clinical rationale and specific criteria UHC used to set the quantity limit.
• Concurrent appeal + urgent supply: Ask your HTC or prescriber to request an emergency or bridge supply from the manufacturer's patient assistance program while the appeal proceeds.

## Documentation to Gather

1. Pharmacokinetic (PK) study results — if your HTC performed PK testing to individualize your dosing, this is the single most powerful document. It directly demonstrates why the standard quantity is insufficient for your physiology. 2. Prescriber's detailed medical-necessity letter — should explain the prescribed quantity, the calculation method (weight-based per FDA label), and the clinical consequence of under-dosing (breakthrough bleeds, joint damage). 3. Bleeding diary or annualized bleed rate (ABR) — documentation of breakthrough bleeds on lower doses, if applicable. 4. Body weight and relevant labs — current weight from chart, any inhibitor titer results, and Factor VIII recovery data. 5. UHC's quantity limit policy — print UHC's current medical/coverage policy and identify the exact QL threshold and any exception criteria listed. 6. FDA prescribing label — the dosing and administration section explicitly permits dose individualization; cite the label language directly in your appeal.

## Criteria-Mapping Structure

Structure your appeal letter as a direct rebuttal of UHC's quantity limit: - Column A: UHC's stated quantity limit and any exception criteria from its coverage policy. - Column B: The specific patient data (weight, PK result, ABR, clinical note) that justifies the prescribed quantity and satisfies each exception criterion.

Close by citing the FDA label's individualization language and requesting that UHC apply clinical judgment rather than a population default to this patient's documented case.